PHAR
- Pharming Group N.V.
()
Overview
Company Summary
Pharming Group N.V. is a biotechnology company specializing in the development and commercialization of innovative therapeutic proteins for the treatment of rare genetic disorders and unmet medical needs. The company is based in the Netherlands and primarily focuses on the production of recombinant proteins using transgenic technology.
Pharming's core area of expertise lies in the production of human proteins, particularly those involved in the human immune response system. Their lead product, Ruconest (conestat alfa), is a recombinant human C1 esterase inhibitor used for the treatment of hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent swelling attacks in various body parts.
Ruconest is derived from the milk of rabbits that have been genetically modified to produce human C1 esterase inhibitor. This unique production system allows for a controlled and consistent supply of the therapeutic protein, reducing the risk of contamination and ensuring a high-quality product.
Pharming also has an active research and development pipeline focusing on genetic disorders and therapeutic areas such as Pompe disease, Fabry disease, and pre-eclampsia. The company collaborates with various academic and industry partners to advance their pipeline and explore new treatment options.
In addition to product development, Pharming is engaged in the commercialization and marketing of its products globally. The company partners with distributors and healthcare providers to ensure the availability of their products to patients in different regions. They also invest in clinical studies and regulatory activities to expand product indications and achieve regulatory approvals.
Overall, Pharming Group N.V. is dedicated to improving the lives of patients with rare genetic disorders through the development and commercialization of innovative therapeutic proteins. Their unique transgenic technology platform and focus on rare diseases differentiate them in the biotechnology industry.